An Economic Boost for an Unlikely Target :The Scientist [2006-12-01]


	The article you are attempting to read is Premium content which is only available to our online subscribers.

Subscribing to The Scientist is easy and inexpensive.

And you can choose from many options. Try us out with an online day pass starting at only $4.95. Or, get it all with unlimited online access to The Scientist Archive and door-to-door delivery of our monthly print magazine.


	The Scientist also offers site licenses to institutions and organizations. When your librarian adds The Scientist to the library's collection, you can get unlimited online access through your place of work or study. Recommend The Scientist today



An Economic Boost for an Unlikely Target Even though the National Academy of Science listed it as a top priority in 1999, cytomegalovirus (CMV) vaccine development has languished in a pharmaceutical backwater until recently. It was considered a money pit. "They've spent massive amounts of money already," says Gerd Maul, a virologist at the Wistar Institute in Philadelphia.